Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-11-04

Clinical Trial Update: Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001) [Phase 1]

View source ↗

Summary

Phase 1 trial of MK-1248 with and without pembrolizumab in participants with advanced solid tumors was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MK-1248
  • Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Solid Tumor | Phase 1 | Status: TERMINATED | Results posted: 2019-11-04